RSS

Cypralis

Licence terms for the exclusive development and commercialisation rights to certain macrocyclic inhibitors of peptide bond isomerases (cyprolides) have been agreed upon by Cypralis and Gilead Sciences. more

News

A quick review of some recent treatment approvals, clinical studies and general news in curing diseases, affecting patients from top to bottom. more

News

Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has entered into a collaboration with Janssen Pharmaceuticals more

News